Acadia adopts a new PhIII game plan for 'breakthrough' med, dumps Alzheimer's PhII
Acadia $ACAD has decided to change the game for its drug Nuplazid (pimavanserin) going further into Phase III, after the FDA handed out its breakthrough drug designation for the therapy.
Approved already for Parkinson’s disease psychosis, the biotech had been setting the stage for a pivotal trial in Alzheimer’s disease psychosis for their 5-HT2A therapy. But in announcing the launch of their HARMONY study, execs say now that they will recruit a mix of patients with Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease dementia, vascular dementia and frontotemporal dementia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.